Vesper Bio Reports Positive Phase Ib/Iia Topline Data For VES001
31 Oct 2025 //
PHARMIWEB
Vesper Bio Announces Successful Ph I Study for Frontotemporal Dementia Treatment
04 Sep 2024 //
PR NEWSWIRE
Vesper Bio Completes SAD In FTD Trial Of VES001 Drug Candidate
30 May 2024 //
PR NEWSWIRE

Market Place
Sourcing Support